{"hands_on_practices": [{"introduction": "Monitoring the response to syphilis therapy is a cornerstone of effective management, primarily guided by changes in nontreponemal test titers like the Rapid Plasma Reagin (RPR). The established clinical benchmark for an adequate response in early syphilis is a \"fourfold,\" or two-dilution, decrease in titer. This practice exercise challenges you to translate this clinical rule into a precise quantitative measure, reinforcing the mathematical basis of serological monitoring. [@problem_id:4457053]", "problem": "A patient with early syphilis has a baseline Rapid Plasma Reagin (RPR) titer of $1{:}32$. In nontreponemal testing, titers are reported in a geometric series of doubling serial dilutions $1{:}1, 1{:}2, 1{:}4, 1{:}8, 1{:}16, 1{:}32, \\dots$ such that a one-step change corresponds to a multiplicative factor of $2$ in the denominator. Evidence-based management of early syphilis defines an adequate serological treatment response within $6$–$12$ months as a clinically meaningful decline of two dilution steps, operationalized as achieving a titer at or below $1{:}8$ from an initial $1{:}32$. Using only the properties of serial doubling dilutions and the definition of a two-step decline, compute the fold-change threshold as the ratio of the baseline titer to the largest follow-up titer consistent with adequate response. Report this fold-change as a single real number. No rounding is required, and no units are to be included in the final answer.", "solution": "The problem requires the computation of a fold-change threshold based on serological titers for syphilis. A rigorous validation of the problem statement is the necessary first step.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n-   Baseline Rapid Plasma Reagin (RPR) titer: $1{:}32$\n-   Titer series: Geometric series of doubling serial dilutions $1{:}1, 1{:}2, 1{:}4, 1{:}8, 1{:}16, 1{:}32, \\dots$\n-   Step definition: A one-step change corresponds to a multiplicative factor of $2$ in the denominator.\n-   Adequate response definition: A decline of two dilution steps from an initial $1{:}32$ titer, operationalized as achieving a titer at or below $1{:}8$.\n-   Task: Compute the fold-change threshold.\n-   Fold-change threshold definition: The ratio of the baseline titer to the largest follow-up titer consistent with adequate response.\n-   Output format: A single real number.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded**: The problem is based on established principles of serological testing (nontreponemal tests like RPR) and clinical guidelines for monitoring syphilis treatment. The use of serial dilutions, titers, and the criterion of a four-fold (or two-dilution step) decline for adequate response are standard in clinical practice. The premises are factually sound.\n-   **Well-Posed**: The problem provides all necessary information. The quantities to be used—baseline titer, the condition for an adequate response, and the largest follow-up titer satisfying this condition—are explicitly defined or can be uniquely determined from the definitions. The task is to compute a specific, well-defined ratio.\n-   **Objective**: The language is precise and unbiased. Clinical terms like \"adequate serological treatment response\" are immediately operationalized with specific numerical criteria (\"at or below $1{:}8$\").\n\n**Step 3: Verdict and Action**\nThe problem is scientifically grounded, self-contained, and well-posed. It is deemed **valid**. A solution will be derived.\n\n**Solution Derivation**\n\nThe problem revolves around the concept of serological titers, which are expressed as ratios representing the highest dilution of a serum sample that still produces a positive reaction. A titer of the form $1{:}D$ indicates a dilution by a factor of $D$.\n\nLet a titer $T$ be represented by its dilution factor $D$. This is a standard convention where a \"higher\" or \"stronger\" titer (indicating a greater concentration of antibodies) corresponds to a larger value of $D$.\nThe baseline titer given is $T_{baseline} = 1{:}32$. Its numerical value, representing the dilution factor, is $D_{baseline} = 32$.\n\nThe problem states that an adequate treatment response is characterized by a \"decline\" in titer. A decline from a stronger reaction ($1{:}32$) to a weaker reaction ($1{:}16$, for example) corresponds to a decrease in the dilution factor $D$. This is confirmed by the statement that a two-step decline from $1{:}32$ results in a titer of $1{:}8$, showing that the denominator decreases with each step of decline ($32 \\rightarrow 16 \\rightarrow 8$).\n\nThe condition for an adequate response is that the follow-up titer, $T_{followup} = 1{:}D_{followup}$, must be \"at or below $1{:}8$\". Following the logic of a titer decline, this means the dilution factor $D_{followup}$ must be less than or equal to $8$. The set of possible follow-up titers consistent with an adequate response, given the geometric series of dilutions, is $\\{1{:}8, 1{:}4, 1{:}2, 1{:}1, \\dots\\}$.\n\nThe problem requires using \"the largest follow-up titer consistent with adequate response\". In serology, the \"largest\" or \"highest\" titer is the one that is still reactive at the highest dilution, which corresponds to the largest dilution factor $D$. From the set of adequate response titers, the one with the largest dilution factor is $1{:}8$.\nLet this specific follow-up titer be $T_{fu,max}$.\n$$ T_{fu,max} = 1{:}8 $$\nThe numerical value of its dilution factor is $D_{fu,max} = 8$.\n\nThe fold-change threshold is defined as the ratio of the baseline titer to this largest follow-up titer. This is interpreted as the ratio of their numerical dilution factors.\nLet the fold-change be denoted by $F$.\n$$ F = \\frac{D_{baseline}}{D_{fu,max}} $$\n\nSubstituting the values derived:\n$$ F = \\frac{32}{8} $$\n$$ F = 4 $$\n\nThis result is consistent with the initial description of an adequate response. A \"decline of two dilution steps\" where each step involves a factor of $2$ in the denominator implies a total change in the denominator by a factor of $2^2 = 4$. The baseline denominator is $32$, and a change by a factor of $4$ yields $32/4 = 8$, which is precisely the threshold for adequate response. The computed fold-change of $4$ represents this clinically significant four-fold drop in titer.", "answer": "$$\\boxed{4}$$", "id": "4457053"}, {"introduction": "The diagnosis of neurosyphilis is one of the most challenging aspects of syphilis management, often requiring the synthesis of subtle clinical signs with imperfect laboratory data. While a reactive cerebrospinal fluid (CSF) VDRL test is highly specific, its limited sensitivity means a nonreactive result cannot exclude the diagnosis in a patient with high clinical suspicion. This problem places you in a realistic clinical scenario where you must apply principles of diagnostic test performance—including pre-test probability and the implications of test sensitivity—to justify a treatment decision in the face of an apparently negative key test. [@problem_id:4457080]", "problem": "A patient with suspected neurosyphilis presents with progressive cognitive decline, wide-based gait, and asymmetric sensorineural hearing loss over the past $6$ months. He has a known history of untreated early syphilis diagnosed $1$ year ago with a serum nontreponemal titer of $1{:}64$ at that time. Current serum testing shows a reactive nontreponemal test with titer $1{:}32$ and a reactive treponemal test. Human Immunodeficiency Virus (HIV) serology is negative. Lumbar puncture reveals an opening pressure of $210\\,\\mathrm{mm\\,H_2O}$, cerebrospinal fluid (CSF) white blood cell count $35\\,\\mathrm{cells/mm^3}$ (predominantly lymphocytes), CSF protein $95\\,\\mathrm{mg/dL}$, CSF glucose $55\\,\\mathrm{mg/dL}$ (serum glucose $95\\,\\mathrm{mg/dL}$), a nonreactive CSF Venereal Disease Research Laboratory (VDRL) test, and a reactive CSF Fluorescent Treponemal Antibody Absorption (FTA-ABS) test.\n\nUsing definitions from diagnostic test performance and the principles of therapeutic decision-making, explain why a negative CSF VDRL does not exclude neurosyphilis in this symptomatic patient and select the most appropriate management. Your reasoning should start from fundamental definitions: sensitivity ($\\text{sensitivity} = P(\\text{test positive} \\mid \\text{disease})$), specificity ($\\text{specificity} = P(\\text{test negative} \\mid \\text{no disease})$), pretest probability, Bayes’ theorem, and tissue penetration requirements for antimicrobial therapy. Then choose the single best option below that integrates these principles to justify management in this case.\n\nA. A negative CSF VDRL excludes neurosyphilis because the CSF VDRL has high sensitivity; therefore, defer therapy and repeat the lumbar puncture only if symptoms persist.\n\nB. In symptomatic patients with high pretest probability and CSF pleocytosis and elevated protein, a nonreactive CSF VDRL does not exclude neurosyphilis due to limited sensitivity; treatment with intravenous aqueous crystalline penicillin G $18$ to $24$ million units per day (e.g., $3$ to $4$ million units every $4$ hours) for $10$ to $14$ days is indicated.\n\nC. Delay therapy until the CSF VDRL becomes reactive on repeat testing, because a reactive CSF treponemal test is nonspecific and cannot support treatment without a reactive CSF VDRL.\n\nD. Administer intramuscular benzathine penicillin G $2.4$ million units weekly for $3$ weeks, which achieves adequate CSF levels even if neurosyphilis is present, avoiding the need for hospitalization.\n\nE. For penicillin-allergic patients, oral doxycycline for $28$ days is adequate for neurosyphilis, and desensitization to penicillin is unnecessary because doxycycline penetrates the CSF sufficiently in all cases.", "solution": "The question asks for a principle-based justification that a negative CSF Venereal Disease Research Laboratory (VDRL) test does not exclude neurosyphilis in a patient with compatible neurologic symptoms and CSF abnormalities, and then for the appropriate management.\n\nWe begin from core definitions:\n\n- Sensitivity is defined as $\\text{sensitivity} = P(\\text{test positive} \\mid \\text{disease})$, the probability a test is positive given that disease is present.\n- Specificity is defined as $\\text{specificity} = P(\\text{test negative} \\mid \\text{no disease})$, the probability a test is negative given that disease is absent.\n- Bayes’ theorem integrates pretest probability (the clinician’s estimate of $P(\\text{disease})$ before testing) with test characteristics to yield a post-test probability. In the context of a negative test, the negative likelihood ratio is $\\mathrm{LR^{-}} = \\dfrac{1 - \\text{sensitivity}}{\\text{specificity}}$, and the posterior odds equal prior odds multiplied by $\\mathrm{LR^{-}}$.\n- A test with limited sensitivity cannot reliably rule out disease when the pretest probability is high; the post-test probability may remain above a therapeutic threshold even after a negative result.\n- For antimicrobial management, neurosyphilis requires drug concentrations in the CSF that are reliably bactericidal against Treponema pallidum. Aqueous crystalline penicillin G, administered intravenously at high doses, achieves therapeutic CSF levels, particularly when the meninges are inflamed. In contrast, intramuscular benzathine penicillin G does not achieve adequate CSF concentrations. In penicillin allergy, desensitization to penicillin or the use of agents with supportive data for CSF penetration (e.g., ceftriaxone) may be considered, whereas oral doxycycline is not recommended as definitive therapy for neurosyphilis due to variable CSF penetration and insufficient evidence.\n\nApplying these to the scenario:\n\n- The pretest probability of neurosyphilis is high because the patient has progressive cognitive decline, gait abnormalities, and cranial nerve involvement (hearing loss), all compatible with neurosyphilis, along with reactive serum treponemal and nontreponemal tests. The CSF demonstrates pleocytosis ($35\\,\\mathrm{cells/mm^3}$), elevated protein ($95\\,\\mathrm{mg/dL}$), and reactive CSF Fluorescent Treponemal Antibody Absorption (FTA-ABS), all supporting central nervous system involvement by syphilis.\n- The CSF VDRL is widely recognized to have high specificity but limited sensitivity for neurosyphilis. That is, $P(\\text{negative} \\mid \\text{disease})$ is not negligible; therefore, $1 - \\text{sensitivity}$ can be substantial. With limited sensitivity, a nonreactive result cannot exclude disease, especially when the pretest probability is high. The negative likelihood ratio $\\mathrm{LR^{-}}$ is not sufficiently small to drive the post-test probability below treatment thresholds in such cases.\n- Bayes’ theorem dictates that when prior odds are high, multiplication by a moderate $\\mathrm{LR^{-}}$ still yields high posterior odds, justifying treatment.\n\nTherapy must be chosen to achieve adequate CSF levels. Aqueous crystalline penicillin G $18$ to $24$ million units per day intravenously (e.g., $3$ to $4$ million units every $4$ hours) for $10$ to $14$ days is the recommended regimen. Benzathine penicillin G $2.4$ million units intramuscularly weekly for $3$ weeks, preferred for late latent syphilis without central nervous system involvement, does not penetrate the CSF adequately and is inappropriate for neurosyphilis. Oral doxycycline is not recommended for neurosyphilis due to insufficient evidence for efficacy and variable CSF penetration; penicillin desensitization is preferred if penicillin allergy is present, with ceftriaxone considered as an alternative in selected circumstances.\n\nOption-by-option analysis:\n\n- Option A: States that the CSF VDRL has high sensitivity and that a negative result excludes neurosyphilis and recommends deferring therapy. This contradicts well-established test characteristics: CSF VDRL is highly specific but has limited sensitivity. A negative result cannot exclude neurosyphilis in a high pretest probability scenario. Verdict: Incorrect.\n\n- Option B: Correctly recognizes that in a symptomatic patient with CSF pleocytosis and elevated protein, a nonreactive CSF VDRL does not exclude neurosyphilis due to limited sensitivity. It integrates pretest probability and the totality of CSF abnormalities and clinical findings, and it recommends the appropriate intravenous aqueous crystalline penicillin G regimen ($18$ to $24$ million units per day for $10$ to $14$ days). Verdict: Correct.\n\n- Option C: Advises delaying therapy until CSF VDRL becomes reactive, discounting reactive CSF treponemal tests and other CSF abnormalities. This violates principles of test interpretation: in high pretest probability contexts, a sensitive but nonspecific test (CSF FTA-ABS) can support diagnosis, and high specificity of CSF VDRL with limited sensitivity means waiting for reactivity risks harm. Treatment should not be delayed. Verdict: Incorrect.\n\n- Option D: Recommends intramuscular benzathine penicillin G, asserting adequate CSF levels. Pharmacokinetic principles indicate benzathine penicillin G does not achieve therapeutic CSF concentrations; it is inappropriate for neurosyphilis. Verdict: Incorrect.\n\n- Option E: Recommends oral doxycycline for neurosyphilis and dismisses penicillin desensitization. Doxycycline has variable CSF penetration and insufficient evidence for neurosyphilis cure; penicillin desensitization with subsequent intravenous penicillin G is preferred. Verdict: Incorrect.\n\nTherefore, the most appropriate explanation and management are given in Option B.", "answer": "$$\\boxed{B}$$", "id": "4457080"}, {"introduction": "The standard multi-week regimen of benzathine penicillin G for latent syphilis requires consistent patient adherence, but missed or delayed doses are a common clinical reality. This exercise moves beyond rote memorization of dosing schedules to a deeper, quantitative understanding of the treatment's pharmacokinetics. By modeling the decay of penicillin concentrations and the additive effect of multiple doses, you can determine the maximum permissible delay between injections, providing an evidence-based foundation for patient counseling and managing scheduling challenges. [@problem_id:4457139]", "problem": "A patient with late latent syphilis is prescribed three weekly intramuscular doses of benzathine penicillin G, each nominally given at $7$-day intervals. The treatment objective is to maintain serum penicillin concentrations at or above the treponemicidal minimal inhibitory concentration $M$ continuously until the next injection, in order to avert treatment failure. Assume a one-compartment pharmacokinetic model with first-order elimination and superposition: each injection produces an effective initial concentration $A$ that decays as $A \\exp(-k t)$, where $k$ is the apparent first-order rate constant, and the total concentration at time $t$ is the sum of the contributions from all prior injections. The minimal inhibitory concentration is $M$, and the apparent half-life is $t_{1/2}$, so that $k = (\\ln 2)/t_{1/2}$. As a conservative clinical policy constraint, use the widely adopted rule that the inter-dose interval must not exceed $14$ days; otherwise the series is considered interrupted and should be restarted. This rule is stated by the Centers for Disease Control and Prevention (CDC).\n\nUsing only these principles and facts, and taking $A = 0.040$ mg/L, $M = 0.018$ mg/L, and $t_{1/2} = 10$ days, do the following:\n- Derive an expression for the latest allowable time $t_{2}^{\\max}$ (in days since the first injection at $t=0$) for the second injection such that the serum concentration remains $\\geq M$ up to $t_{2}^{\\max}$.\n- Derive an expression for the latest allowable interval $\\Delta_{23}^{\\max}$ (in days after the second injection) for the third injection such that the serum concentration remains $\\geq M$ up to the third injection, taking the worst-case scenario in which the second injection is administered at its latest allowable time $t_{2}^{\\max}$.\n- Define the acceptable scheduling window beyond the nominal weekly target for the second injection as $W_{2} = \\min\\{t_{2}^{\\max} - 7,\\; 14 - 7\\}$, and for the third injection as $W_{3} = \\min\\{\\Delta_{23}^{\\max} - 7,\\; 14 - 7\\}$, both in days.\nCompute $W_{2}$ and $W_{3}$ numerically, rounding your results to three significant figures. Express the final answer in days. The final answer must be a single row matrix containing $W_{2}$ and $W_{3}$ in that order.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n**Step 1: Extract Givens**\n- Patient with late latent syphilis is treated with three weekly intramuscular doses of benzathine penicillin G.\n- Nominal inter-dose interval: $7$ days.\n- Treatment objective: serum penicillin concentration $C(t) \\geq M$ continuously, where $M$ is the minimal inhibitory concentration.\n- Pharmacokinetic model: one-compartment, first-order elimination, superposition.\n- Concentration from a single injection at time $t=0$: $C(t) = A \\exp(-k t)$.\n- $A$: effective initial concentration.\n- $k$: apparent first-order rate constant.\n- Relation between rate constant and half-life: $k = (\\ln 2)/t_{1/2}$.\n- Clinical policy constraint: inter-dose interval must not exceed $14$ days.\n- Given values: $A = 0.040$ mg/L, $M = 0.018$ mg/L, $t_{1/2} = 10$ days.\n- $t_{2}^{\\max}$: latest allowable time (in days since $t=0$) for the second injection.\n- $\\Delta_{23}^{\\max}$: latest allowable interval (in days after the second injection at $t_{2}^{\\max}$) for the third injection.\n- Acceptable scheduling windows:\n  - $W_{2} = \\min\\{t_{2}^{\\max} - 7,\\; 14 - 7\\}$\n  - $W_{3} = \\min\\{\\Delta_{23}^{\\max} - 7,\\; 14 - 7\\}$\n- The final numerical results for $W_{2}$ and $W_{3}$ are to be rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, employing a standard one-compartment pharmacokinetic model which is a common and valid simplification in clinical pharmacology. The principle of superposition for multiple doses is correct for linear pharmacokinetic systems. The parameters provided ($A$, $M$, $t_{1/2}$) are realistic for benzathine penicillin G. The problem is well-posed, as all necessary information is provided to derive a unique solution. The language is objective and formal. The incorporation of a clinical guideline (the $14$-day rule) alongside the pharmacokinetic model makes the problem a relevant and practical application of mathematical modeling in a clinical context.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A full solution will be provided.\n\nThe first step is to calculate the elimination rate constant, $k$, from the given half-life, $t_{1/2}$.\n$$k = \\frac{\\ln 2}{t_{1/2}} = \\frac{\\ln 2}{10} \\text{ days}^{-1}$$\n\n**Derivation of the latest time for the second injection, $t_{2}^{\\max}$**\nThe first injection is administered at $t=0$. The concentration due to this single injection at any time $t>0$ is given by $C_{1}(t) = A \\exp(-kt)$. The second injection is due at time $t_{2}$. To prevent treatment failure, the concentration must remain at or above $M$ for the entire interval $[0, t_{2}]$. Since $C_{1}(t)$ is a monotonically decreasing function for $t>0$, the minimum concentration in this interval occurs just before the second injection is administered, at $t=t_{2}$.\nTherefore, the limiting condition is:\n$$C_{1}(t_{2}) \\geq M$$\nTo find the maximum possible time $t_{2}^{\\max}$, we set the concentration to the minimum allowable level:\n$$A \\exp(-k t_{2}^{\\max}) = M$$\nSolving for $t_{2}^{\\max}$:\n$$\\exp(-k t_{2}^{\\max}) = \\frac{M}{A}$$\n$$-k t_{2}^{\\max} = \\ln\\left(\\frac{M}{A}\\right)$$\n$$t_{2}^{\\max} = -\\frac{1}{k} \\ln\\left(\\frac{M}{A}\\right) = \\frac{1}{k} \\ln\\left(\\frac{A}{M}\\right)$$\nSubstituting the expression for $k$:\n$$t_{2}^{\\max} = \\frac{t_{1/2}}{\\ln 2} \\ln\\left(\\frac{A}{M}\\right)$$\nNumerically, this is:\n$$t_{2}^{\\max} = \\frac{10}{\\ln 2} \\ln\\left(\\frac{0.040}{0.018}\\right) = \\frac{10}{\\ln 2} \\ln\\left(\\frac{20}{9}\\right) \\approx 11.517 \\text{ days}$$\n\n**Derivation of the latest interval for the third injection, $\\Delta_{23}^{\\max}$**\nThis calculation is based on the worst-case scenario where the second injection is administered at its latest possible time, $t_{2} = t_{2}^{\\max}$. The third injection is to be administered at time $t_{3} = t_{2}^{\\max} + \\Delta_{23}$. For $t \\geq t_{2}^{\\max}$, the total concentration, $C_{\\text{total}}(t)$, is the sum of the concentrations from the first injection (at $t=0$) and the second injection (at $t=t_{2}^{\\max}$):\n$$C_{\\text{total}}(t) = A \\exp(-kt) + A \\exp(-k(t - t_{2}^{\\max}))$$\nThe concentration must remain at or above $M$ for the entire interval $[t_{2}^{\\max}, t_3]$. Since $C_{\\text{total}}(t)$ is a sum of two monotonically decreasing functions, it is also monotonically decreasing. The minimum concentration in this interval occurs just before the third injection at $t=t_{3}$.\nThe limiting condition is:\n$$C_{\\text{total}}(t_{3}) = M$$\n$$A \\exp(-kt_{3}) + A \\exp(-k(t_{3} - t_{2}^{\\max})) = M$$\nSubstitute $t_{3} = t_{2}^{\\max} + \\Delta_{23}^{\\max}$:\n$$A \\exp(-k(t_{2}^{\\max} + \\Delta_{23}^{\\max})) + A \\exp(-k((t_{2}^{\\max} + \\Delta_{23}^{\\max}) - t_{2}^{\\max})) = M$$\n$$A \\exp(-k t_{2}^{\\max}) \\exp(-k \\Delta_{23}^{\\max}) + A \\exp(-k \\Delta_{23}^{\\max}) = M$$\nFrom the derivation of $t_{2}^{\\max}$, we know that $A \\exp(-k t_{2}^{\\max}) = M$. Substituting this into the equation:\n$$M \\exp(-k \\Delta_{23}^{\\max}) + A \\exp(-k \\Delta_{23}^{\\max}) = M$$\nFactor out the exponential term:\n$$(A+M) \\exp(-k \\Delta_{23}^{\\max}) = M$$\nSolving for $\\Delta_{23}^{\\max}$:\n$$\\exp(-k \\Delta_{23}^{\\max}) = \\frac{M}{A+M}$$\n$$-k \\Delta_{23}^{\\max} = \\ln\\left(\\frac{M}{A+M}\\right)$$\n$$\\Delta_{23}^{\\max} = -\\frac{1}{k} \\ln\\left(\\frac{M}{A+M}\\right) = \\frac{1}{k} \\ln\\left(\\frac{A+M}{M}\\right) = \\frac{1}{k} \\ln\\left(1 + \\frac{A}{M}\\right)$$\nSubstituting the expression for $k$:\n$$\\Delta_{23}^{\\max} = \\frac{t_{1/2}}{\\ln 2} \\ln\\left(1 + \\frac{A}{M}\\right)$$\nNumerically, this is:\n$$\\Delta_{23}^{\\max} = \\frac{10}{\\ln 2} \\ln\\left(1 + \\frac{0.040}{0.018}\\right) = \\frac{10}{\\ln 2} \\ln\\left(1 + \\frac{20}{9}\\right) = \\frac{10}{\\ln 2} \\ln\\left(\\frac{29}{9}\\right) \\approx 16.879 \\text{ days}$$\n\n**Computation of the acceptable scheduling windows, $W_{2}$ and $W_{3}$**\nThe acceptable scheduling window is defined as the maximum number of days a dose can be delayed beyond its nominal $7$-day target, while satisfying both the pharmacokinetic requirement ($C \\geq M$) and the clinical guideline (interval $\\leq 14$ days).\n\nFor the second injection, the nominal time is $t=7$ days. The latest time is $t_{2}^{\\max} \\approx 11.517$ days. The maximum allowable interval from the first injection is also constrained by the clinical guideline to be $14$ days. The additional time allowed beyond the nominal $7$-day mark is therefore the minimum of the leeway granted by the pharmacokinetics and the leeway granted by the clinical guideline.\nThe leeway from pharmacokinetics is $t_{2}^{\\max} - 7 \\approx 11.517 - 7 = 4.517$ days.\nThe leeway from the clinical guideline is $14 - 7 = 7$ days.\n$$W_{2} = \\min\\{t_{2}^{\\max} - 7,\\; 14 - 7\\} = \\min\\{4.517, 7\\} = 4.517 \\text{ days}$$\nRounding to three significant figures, $W_{2} = 4.52$ days.\n\nFor the third injection, the nominal interval after the second dose is $7$ days. The latest allowable interval, given the worst-case timing of the second dose, is $\\Delta_{23}^{\\max} \\approx 16.879$ days. The maximum interval is also constrained by the clinical guideline to be $14$ days.\nThe leeway from pharmacokinetics is $\\Delta_{23}^{\\max} - 7 \\approx 16.879 - 7 = 9.879$ days.\nThe leeway from the clinical guideline is $14 - 7 = 7$ days.\n$$W_{3} = \\min\\{\\Delta_{23}^{\\max} - 7, \\; 14 - 7\\} = \\min\\{9.879, 7\\} = 7 \\text{ days}$$\nRounding to three significant figures, $W_{3} = 7.00$ days.", "answer": "$$\\boxed{\\begin{pmatrix} 4.52 & 7.00 \\end{pmatrix}}$$", "id": "4457139"}]}